Supported by JSPS KAKENHI Grant Number JP18K16956 and the Japan Foundation for Applied Enzymology (VBIC).
Disclosures: S. Sakimoto, Alcon Pharma (R), Santen (R), Bayer (R), Senju (R); T. Okazaki, None; S. Usui, None; T. Ishibashi, None; Y. Oura, None; K. Nishida, None; A. Miki, Pfizer (R), Santen (R), Otsuka Pharmaceutical (R), Alcon Pharma (R), R-Tech Ueno (R), Kowa (R), Ellex Japan (R); R. Kawasaki, Novartis (F, R), Pfizer (F, R), Senju (F, R), Bayer (F, R), Novo Nordisk (C), Office Future (C), MICIN (C), Predictive Analytics (C), Alcon Pharma (R), Kowa (R), Santen (R), Topcon (R); K. Matsushita, Alcon Pharma (F, R), Novartis (F), Pfizer (F, R), Kowa (R), Otsuka (R), Santen (R), Senju (R); H. Sakaguchi, Menicon (R); K. Nishida, Alcon Pharma (F, R), AMO (F), Bayer (F, R), HOYA (F), Kowa (F, R), Menicon (F), MSD (F), Novartis (F, R), Otsuka (F, R), Pfizer (F, R), Rhoto (F), Santen (F, R), Senju (F, R), Topcon (F), Wakamoto (F), Boehringer Ingelheim (R), Chuo Sangio (R), HOYA (R), Johnson & Johnson (R), SEED (R)